| # | Date | Analyst Firm | Upside/Downside | Price Target Change | Rating Change | Current Rating |
|---|
Kalaris Therapeutics (NASDAQ:KLRS) reported quarterly losses of $(0.64) per share which beat the analyst consensus estimate of ...
Citizens analyst Jonathan Wolleben initiates coverage on Kalaris Therapeutics (NASDAQ:KLRS) with a Market Outperform rating ...
Kalaris Therapeutics ("Kalaris"), a clinical-stage biopharmaceutical company dedicated to the development and commercia...